Organobalance Medical AG begins business operations
01.12.2010 13:16
Berlin pharmaceutical company is pursuing probiotic-based therapeutic approaches
The newly founded ORGANOBALANCE Medical AG begins its operational business activities on December 1st, 2010. The company was founded by Prof. Dr. Christine Lang, managing partner of ORGANOBALANCE GmbH, and Dr. Bernd Wegener, Chairman of the Federal Association of the Pharmaceutical Industry. V. (BPI) and founder and former CEO of the B•R•A•H•M•S Group.
Facts about ORGANOBALANCE Medical AG
1. Business purpose
ORGANOBALANCE Medical AG finances and promotes the research and development of novel therapeutic approaches by ORGANOBALANCE GmbH, based on positive microorganisms, so-called specific probiotic cultures. The aim is to create patent-protected active ingredients for novel medications and medical devices. Out-licensing of the research and development results achieved is not ruled out. In this way, new therapy options are to be created for indications that have not yet been satisfactorily treated.
2. Board of Directors
The board of directors of the stock corporation consists of the two company founders. Her work focuses on the scientific-technical area (Prof. C. Lang, Chief Scientific Officer) and the sales-legal area (Dr. B. Wegener, Chief Executive Officer).
Due to their previous and current activities, both board members have extensive experience and recognized expertise in their areas of work.
3. Supervisory Board
The supervisory board of the new company will consist of:
1. Attorney Renke Lührs, Berlin (Chairman)
2. Dipl. Ing. Joachim Lang, Ulm (deputy chairman)
3. Prof. Dr. Ulf Stahl, Berlin
4. Motivation to start a business
Ms. Prof. Lang and Mr. Dr. Wegener founded ORGANOBALANCE Medical AG with the aim of transferring the patented results of ORGANOBALANCE GmbH's own long-term research work into marketable products and exploiting the potential therein. ORGANOBALANCE GmbH will continue to pursue its successful research and development work as a service provider in the tried and tested manner.
An example of ORGANOBALANCE GmbH's own research work is a product for the probiotic therapy of stomach ulcers caused by the germ Helicobacter pylori. What is new is the granting of a US patent for the use of the strains developed by ORGANOBALANCE GmbH for this biological indication. Such a product would hit a global market in which chemical therapeutics worth several hundred million euros are currently sold per year.
“I am very pleased to be able to continue with ORGANOBALANCE Medical AG to pursue the excellent research results that we were able to achieve in our own projects with ORGANOBALANCE GmbH on biological active ingredients and to transfer them into practical applications. “We are opening up previously unknown therapeutic approaches to patients and doctors,” says Prof. Lang, describing her expectations of the new company.
“Based on our biological active ingredients, we want and can develop alternatives to current medications, which often have side effects and are not always satisfactorily effective,” says Dr. Wegener continues and adds: “With our know-how and our patents, we have the best prerequisites for this.”
5. Current projects
In addition to the gastric therapeutic drug mentioned, other projects in the area of difficult-to-treat skin diseases are currently being pursued. What all projects have in common is that, as requested by many patients, they are intended to offer alternatives to chemical-synthetic therapies based on lactobacillus and yeast strains that are harmless to health.
6. Personnel
In order to achieve their goals, ORGANOBALANCE GmbH and ORGANOBALANCE Medical AG plan to expand their workforce of specialized scientists and experts. The companies can offer them secure jobs and attractive prospects due to their secure financing, their unique know-how and the patent protection of the working principles.